The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
high discontinuation rates (e.g., 5067 %% at one year and 85 % at two years [[5], [6], [7], [8]]) that may relate to side effects, costs, variable individual efficacy, or patient preferences [5,9]
Playbook Price increase versus pack-size reduction
Of the 39 companies we reviewed, 13% are publicly traded and 44% are venture-backed
It's worth noting that tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, representing a distinct but related medication class with similar clinical effects
employers heading into 2027, a trend driven by climbing overall costs that have persisted even as the per-unit price of individual medications has declined